ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2016
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- Thymic epithelial tumors: what's next?Cancer metastasis reviews · 2026Review
- Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Transforming Growth Factor-β1 as a Biomarker of Malignant Behavior and PD-L1 Expression in Thymic Epithelial Tumors.Cancer science · 2026Article
- Proteasome inhibition as a potential therapeutic target in thymic cancer.Cell death & disease · 2025Article
- Therapeutic Management of Metastatic Thymoma and Thymic Carcinoma.Current oncology reports · 2025Review
- Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.Cancer medicine · 2025Review
- The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.International journal of clinical oncology · 2025Article
- Cell Culture Models for Translational Research on Thymomas and Thymic Carcinomas: Current Status and Future Perspectives.Cancers · 2024Review
- Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors.The oncologist · 2024Review
- The Way Ahead: Lessons Learned from Decades of Cancer Research on Thymomas and Thymic Carcinomas.Cancers · 2024Article
- The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Review
- Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Narrative review of indication and management of induction therapy for thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2024Review
- Review
- Emerging therapies in thymic epithelial tumors (Review).Oncology letters · 2023Review
- Thymic Epithelial Tumors: An Evolving Field.Life (Basel, Switzerland) · 2023Review
- Prognostic Value of PIK3R4 Expression and Its Correlation with Immune Cell Infiltration in the Diffuse Large B-cell Lymphoma Microenvironment.Journal of Cancer · 2023Article
- Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThymic epithelial tumors (TETs) are rare tumors originating from the epithelium of the thymus with limited therapeutic options beyond surgery. The pathogenesis of TETs is poorly understood, and the scarcity of model systems for these rare tumors makes the study of their biology very challenging.
methodsA new cell line (MP57) was established from a thymic carcinoma specimen and characterized using standard biomarker analysis, as well as next-generation sequencing (NGS) and functional assays. Sanger sequencing was used to confirm the mutations identified by NGS.
resultsMP57 possesses all the tested thymic epithelial markers and is deemed a bona fide thymic carcinoma cell line. NGS analysis of MP57 identified a mutation in the gene PIK3R2, which encodes a regulatory subunit of PI3K. Further analysis identified different mutations in multiple PI3K subunit genes in another cell line and several primary thymic carcinoma samples, including two catalytic subunits (PIK3CA and PIK3CG) and another regulatory subunit (PIK3R4). Inhibiting PI3K with GDC-0941 resulted in in vitro antitumor activity in TET cells carrying mutant PI3K subunits.
conclusionsAlterations of PI3K due to mutations in its catalytic or regulatory subunits are observed in a subgroup of TETs, in particular, thymic carcinomas. Targeting PI3K may be an effective strategy to treat these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.